Bannerbild German Brest Group

GBG Forschungs GmbH – a leading breast cancer research institute

GBG Forschungs GmbH is a professional institute dedicated to breast cancer research. It was founded in 2003 by Prof. Dr. med. Gunter von Minckwitz, and lead by Prof. Dr. med. Sibylle Loibl (CEO). The institute serves Germany’s largest breast cancer study group, the German Breast Group, as a platform for implementing academically orientated clinical trials.

Breast cancer research – independent, academic, impartial

GBG Forschungs GmbH is an independent, impartial academic research organisation (ARO). Unlike contract research organisations (CRO), we do not provide research services purely on a contract basis. All study projects have to address an academic question which meets the requirements of the German Breast Group. Through our research, we aim to continually improve the treatment of breast cancer and the quality of the therapy available on a global basis.

Independent breast cancer research – an international leader

When conducting our breast cancer research projects, we adhere to the principles of international academic study groups. Our research institute, together with the German Breast Group’s sub-boards, creates the protocols for our studies as well as our databases and is also responsible for their evaluation and publication – always without influence from the pharmaceutical industry. Examples of our research are the neoadjuvant studies belonging to the “Gepar” trial series.

Today, GBG Forschungs GmbH has clinical data from more than 35,000 breast cancer patients at its disposal. Thanks to our expertise and experience acquired through 30 years of research, we are one of the world’s leading breast cancer research institutes.

Funding of breast cancer research

Our research projects are funded in advance via clinical trials, donations, public funding, the German Cancer Aid Organisation (Deutsche Krebshilfe) and the German Research Foundation (Deutsche Forschungsgemeinschaft). In addition, we receive funding from the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung ─ BMBF) and from foundations, such as the Banss-Stiftung, the Walter-Schulz-Stiftung and the Claudia-von-Schilling-Stiftung, as well as cooperation partners from the pharmaceutical industry. Our Translational Research Division is predominantly funded by the EU, the German Federal Government and various foundations.


German Breast Group: An employer for your future. We are recruiting to expand our multidisciplinary team. Get more information about our current vacancies here.


Do you have any questions about breast cancer? In our patient guide you will find comprehensive information and links to specialized self-help resources.



  • 17.08.2017  Effect of BRCA1/2 Status on Response to Neoadjuvant Carboplatin in TNBC

    Our paper on mutations analysis in the Geparsixto TNBC-Arm was discussed at ASCO-News.

    Mehr ...
  • 05.07.2017  PALOMA-3 Results published

    Palbociclib Combined with Fulvestrant in PremenopausalWomen with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results

    Mehr ...
  • 03.02.2017  How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer?

    Prof. Loibl and Prof. Denkert discuss "How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer?" in the current JCO Editorial.

    Mehr ...
  • GBG Jahrestreffen und AGO Mamma State of the Art

    GBG Jahrestreffen und AGO Mamma State of the Art

    Vom 2. bis 3. März 2017 findet das GBG Jahrestreffen 2017 und am 4. März das AGO Mamma State of the Art-Meeting statt. Weitere Informationen finden Sie hier.

    Mehr ...
  • 31.01.2017  Young Investigator Award

    Young Investigator Award

    Die GBG vergibt einen Reise zum ESMO in Madrid in 2017 für junge Wissenschaftler. Bewerbung ab sofort möglich.

    Mehr ...
  • 08.12.2016  The Lancet - Breast Cancer Series 2016

    The introduction of targeted therapies has profoundly changed the course of some subtypes of breast cancer—but many challenges remain. The Lancet’s 2016 Series on breast cancer discusses the most recent advances in the three most common breast cancer subtypes. The first pair of papers focus on the treatment of advanced oestrogen-receptor-positive and HER2-positive breast cancers, while the third describes how an improved understanding of molecular alterations in the heterogeneous and hard-to-treat triple-negative breast cancer may lead to more refined and more effective therapy.

    Mehr ...
  • 08.11.2016  Tailored, Dense-Dose Chemotherapy for Early Breast Cancer Does Not Result in Significant Improvement in Recurrence-Free Survival

    Among women with high-risk early breast cancer, the use of tailored dose-dense chemotherapy compared with standard adjuvant chemotherapy did not result in a statistically significant improvement in breast cancer recurrence-free survival, and nonhematologic toxic effects were more frequent in the tailored dose-dense group, according to a study appearing in the November 8 issue of JAMA.

    Mehr ...
  • 11.10.2016  Immunotherapy for breast cancer: what does the future hold - BIG Research in Focus now available for download

    BIG Research in Focus - Issue 5, October 2016

    In this issue introduced by Fabrice André (Institut Gustave Roussy, Villejuif, France), leading researchers exchange their views about the potential role of immunotherapies in breast cancer and our current understanding of the immune response to this disease. In addition, an interview of Prof. Gabriel N. Hortobagyi (The University of Texas MD Anderson Cancer Center, USA) gives insight into the trans-Atlantic efforts aiming to move the field of immunotherapies forward faster. We hope you will enjoy the reading.

    Mehr ...
  • 01.08.2016  GAIN 2 – Amendment 3 – neoadjuvanter Behandlungarm ist geöffnet

    GAIN 2 – Amendment 3 – neoadjuvanter Behandlungarm ist geöffnet

    Am 01. August 2016 wurde Amendment 3 der Gain 2 Studie live geschaltet. Es beinhaltet die Öffnung für den neoadjuvanten Behandlungszweig. Zur Erreichung des Rekrutierungsziels (2.886 Patienten) wird die Studie bis QIV 2017 für den Einschluss von Patientinnen geöffnet bleiben.

    Mehr ...
  • 28.07.2016  GBG Annual Meeting 2017 - Save the Date!

    GBG Annual Meeting 2017 - Save the Date!

    Vom 2. bis 3. März 2017 findet in Frankfurt a.M. das GBG Jahrestreffen 2017 statt. Im Anschluss daran findet am 4. März 2017 das AGO Mamma State of the Art Meeting statt. Weitere Informationen finden Sie in unserem Veranstaltungsbereich.

    Mehr ...
  • 14.07.2016  PenelopeB – 50% Rekrutierungsziel erreicht

    PenelopeB – 50% Rekrutierungsziel erreicht

    Am 07. Juli 2016 wurde die 550. Patientin am Krankenhaus Hietzing Wien / Prof. Dr. Sevelda in die PenelopeB Studie randomisiert. Damit wurden 50% der Gesamtrekrutierung erreicht.

    Mehr ...
  • 30.06.2016  INSEMA – 1.000 patients

    INSEMA – 1.000 patients

    Mit Ihrer Hilfe wurde am 30. Juni 2016 die 1.000ste Patientin in die INSEMA-Studie eingeschlossen. Damit ist die geplante Rekrutierungszahl von 5.940 Patienten ein realistisches Ziel. Herzlichen Dank für diese großartige Leistung an alle teilnehmenden Zentren!

    Mehr ...
  • 30.05.2016  Sponsorship award 2015 from the Fritz Acker Foundation

    Sponsorship award 2015 from the Fritz Acker Foundation

    Prof. Dr. med. Sibylle Loibl has won the sponsorship award of the Fritz Acker Foundation in recognition of her research work in the field of oncology.

    Mehr ...
  • 31.03.2016  Guidelines from the Breast Committee of the Working Group for Gynaecological Oncology (AGO)

    The current guidelines from the AGO Breast Committee are published on the AGO’s website.

    Mehr ...
  • 24.03.2016  Order coupon for Breast Care 2016

    Courtesy of the publishing house Karger Verlag, we have again received an order coupon for the “Breast Care” journal 2016. This order coupon entitles GBG members to request a free sample issue or take out a subscription. The form can be downloaded here.

    Mehr ...
  • 08.03.2016  Annual Meeting of the GBG 2016

    Annual Meeting of the GBG 2016

    With over 500 participants, the Annual Meeting was a resounding success. The presentations given on 3 and 4 March will be published in our event archive shortly. Please save the date of the GBG’s next annual meeting: 2 – 3 March 2017.

    Mehr ...
  • 03.03.2016  Relaunch of the website

    All good things take time: the new GBG website has been online since 3 March 2016. We would be pleased to receive your feedback on the new website via the contact form.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd